Regencell Bioscience (RGC) is dealing with a struggling business and Justice Department investigation, yet shares have been surging, Jonathan Weil of The Wall Street Journal reports. The company claims it is developing traditional Chinese medicine to treat autism spectrum disorder and attention-deficit hyperactivity disorder. Despite recurring losses, no revenue, and no salable products, the company ended last week with a $15.5B stock-market value.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGC: